The 2022 iodinated contrast shortage was a supply shock. Getting through it was a decision.
In the spring of 2022, radiology departments around the world opened their cabinets and found a problem they could not scan their way out of. A COVID-19 shutdown at a GE Healthcare plant in Shanghai, the site that produces the widely used iodinated contrast agent iohexol, cut global supply almost overnight. By mid-May, the manufacturer expected an eighty percent reduction in supply through the end of June.¹ Iodinated contrast is not a convenience. It is what makes a CT scan show a pulmonary embolism, a bleed, a tumour. When it runs short, the question is no longer what to image. It is who to image, and with what.
What happened next is the part worth remembering. The shortage was the same for everyone. The outcomes were not.
Some departments cancelled and deferred. Others kept moving, because they could make decisions quickly. They postponed routine treatment-monitoring scans for stable patients to protect contrast for emergencies. They substituted non-contrast CT, MRI or ultrasound where it was clinically safe. Pharmacies repackaged large single-use vials into smaller doses to stretch every millilitre. And the institutions that had signed contracts with more than one supplier simply drew on another source. One academic health system credited exactly that, its enterprise-wide contracts across different vendors, with softening the blow.¹
Look closely at that list and you will notice something. Every one of those responses is a decision, not a product. Substitute. Reallocate. Reprioritize. Switch supplier. The contrast shortage was a supply shock, but getting through it was a decision problem. The departments that came through best were the ones that could see their exposure early and act on it fast, across every site at once.
That is precisely the gap most radiology groups still carry into the next shortage. The data to make those calls usually exists. It sits in the inventory system, the ordering history, the supplier emails, the exam schedule. What is missing is the ability to turn it into the right move before the shelf is empty. And the next shortage is not a hypothetical. The supply of contrast, consumables and spare parts remains concentrated in a handful of plants. The question is not whether disruption returns. It is whether you will be deciding, or scrambling, when it does.
This is the problem Optivian is built for. Optivian is a decision system that sits on top of the systems a radiology group already runs. It does not replace your RIS or your ERP, and it works just as well with the spreadsheets many teams still run on. It does not need a two-year platform build to start. It reads the data you already have, wherever it lives, and turns a supply signal into a clear, ranked action.
When a contrast agent or a critical consumable starts to tighten, Risk and Anomalies flags it early, while there is still room to act. Demand Forecasting shows which sites and which exams are exposed, and when. Then Optivian returns the decision itself, with the reasoning attached:
Buy. Order from an approved alternate supplier, at the right quantity and moment, drawing on the multi-vendor leverage that Spend and Contracts keeps live.
Move. Reallocate stock from a site with surplus to the site at risk, before the shortage becomes a cancelled scan, which Inventory makes visible across the whole network.
Substitute. Use Product Equivalence to identify a clinically approved alternative, so no one is guessing whether the substitute truly matches the protocol.
Renegotiate. Surface the contract worth reopening, with the value at stake attached.
Every recommendation arrives with the full picture: the evidence behind it, the operational and financial impact, the alternatives you are weighing, and a confidence level you can defend to a medical director or a finance team. Actions and KPIs then track whether the decision actually delivered, and the AI Assistant lets anyone ask, in plain language, which sites are exposed and what to do about it. Across MUUTAA deployments, that way of working has meant results such as an eighty-four percent improvement in disruption recognition.²
For a radiology group, the stakes are not abstract. In 2022, the departments that could not decide quickly postponed cancer-monitoring scans and turned patients away.¹ A slow supply decision in imaging is not a line on a variance report. It is a delayed diagnosis. Getting from signal to the right action in hours instead of weeks is not an efficiency metric here. It is the standard of care.
The 2022 shortage ended. The lesson should not. The groups that will handle the next one best are not the ones with the most contrast on the shelf. They are the ones that can decide fastest, across every site, on the systems they already run.
See what a decision system looks like in your network. Talk to MUUTAA.
SOURCES
- Radiological Society of North America (RSNA). “Iodinated Contrast Shortage Challenges Radiologists.” RSNA News, May 2022. A COVID-19 shutdown of a GE Healthcare plant in Shanghai producing iohexol led to an expected eighty percent reduction in supply through the end of June 2022. The article documents institutional responses including deferring non-urgent imaging, substituting non-contrast modalities, repackaging vials, and multi-vendor sourcing.
- Figures reflect results observed across MUUTAA Optivian deployments. Internal MUUTAA data.